FDA notifications. Atazanavir capsule label is updated for pediatric patients.
D000293:Adolescent; D000069446:Atazanavir Sulfate; D002648:Child; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D010372:Pediatrics; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate